Abstract

Drug-target interaction (DTI) is the basis of drug discovery. However, it is time-consuming and costly to determine DTIs experimentally. Over the past decade, various computational methods were proposed to predict potential DTIs with high efficiency and low costs. These methods can be roughly divided into several categories, such as molecular docking-based, pharmacophore-based, similarity-based, machine learning-based, and network-based methods. Among them, network-based methods, which do not rely on three-dimensional structures of targets and negative samples, have shown great advantages over the others. In this article, we focused on network-based methods for DTI prediction, in particular our network-based inference (NBI) methods that were derived from recommendation algorithms. We first introduced the methodologies and evaluation of network-based methods, and then the emphasis was put on their applications in a wide range of fields, including target prediction and elucidation of molecular mechanisms of therapeutic effects or safety problems. Finally, limitations and perspectives of network-based methods were discussed. In a word, network-based methods provide alternative tools for studies in drug repurposing, new drug discovery, systems pharmacology and systems toxicology.

Highlights

  • As the rapid development of systems biology and network pharmacology, the drug discovery paradigm has changed from the linear mode “one drug → one target → one disease” to the network mode “multi-drugs → multi-targets → multi-diseases” (Hopkins, 2008; Medina-Franco et al, 2013; Anighoro et al, 2014)

  • In a 10-fold cross validation process, 10% of the drug-target interactions (DTIs) are randomly extracted from the known DTI network as the test set in turn, while the remnant are used as the training set

  • Compared with those widely used in evaluating machine learning models for prediction of ADMET properties (Cheng et al, 2012a, 2013a) and DTIs (Cheng et al, 2012c), such as sensitivity and specificity, the evaluation indicators from recommender systems are more personalized and suitable for the network-based models that were derived from recommendation algorithms (Cheng et al, 2012b,d; Wu et al, 2016, 2017, 2018; Fang et al, 2017b)

Read more

Summary

Introduction

As the rapid development of systems biology and network pharmacology, the drug discovery paradigm has changed from the linear mode “one drug → one target → one disease” to the network mode “multi-drugs → multi-targets → multi-diseases” (Hopkins, 2008; Medina-Franco et al, 2013; Anighoro et al, 2014). They would meet the challenges that NBI has met, namely predicting potential DTIs for new chemical entities and targets outside of the known DTI network, as well as considering interaction types and binding affinities.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call